Shots:

• Novartis will access Biofourmis' lead digital therapeutics- BiovitalsHF to manage patients with heart failure across Asia- with a potential plan to expand it globally
• The focus of the collaboration is to improve clinical outcomes utilizing Biofourmis' BiovitalsHF along with Biovitals Analytics Engine to identify early signs of HF exacerbations- enabling early interventions in patients with HF with a reduced ejection fraction
• Additionally- Biofourmis acquires Biovotion including its Everion biosensor- combining Biovotion's wearables with Biofourmis' digital therapeutics platform and its AI-driven predictive analytics to offer the most comprehensive digital therapeutics solution for the patients

Source 1- Source 2 to­ read full press release/ article | Ref: PRNewswire- PRNewswire | Image: Twin Cities Business